We reported four cases of pretreated patients with BRAF-mutated advanced melanoma, who were rechallenged with off-label targeted therapy after immunotherapy with single agents (at least anti-PD-1 antibodies), as effective approved therapeutic options were not available. This evidence concerns the gene BRAF and melanoma.